Besplatna dostava putem Box Now paketomata i Overseas kurirske službe iznad 69,99 €.

Provjerite status narudžbe

Pridružite se zajednici ljubitelja knjige iz cijelog svijeta i ostvarite mnoštvo pogodnosti. Izradite besplatni račun

Besplatna dostava Overseas kurirskom službom iznad 69.99 €

DPD kurir 3.99 € DPD točka 3.49 € GLS Kurir 4.99 € GLS paketomat 3.99 € Hrvatska pošta 4.99 € Dostava Overseas 4.99 € Box Now 4.49 €

Kontakt

Kako kupovati

Pomoć

Moj račun

▸ Prazno :-(

Besplatna dostava putem Box Now paketomata i Overseas kurirske službe iznad 69,99 €.

2011 Risk/Benefit Analysis of the Anthrax Vaccine Immunization Program

Name: 2011 Risk/Benefit Analysis of the Anthrax Vaccine Immunization Program
Brand: Biblioscholar
SKU: 08133987
Availability: OutOfStock
Author: Karla L Davis
ISBN: 9781249403371

Karla L Davis

Jezik

Engleski

Knjiga Meki uvez

Libristo kod: 08133987

Nakladnici Biblioscholar, rujan 2012

Safety, efficacy, and legal concerns surrounded the Department of Defense (DoD) Anthrax Vaccine Immu... Cijeli opis

Libristo kod: 08133987

Kupci su kupili i

Regards sur les traditions philosophiques (XIIe-XVIe siecles) Dragos Calma

Tvrdi uvez

106.87 €

Die Folgen der Teilung Schleswigs ? 1920/F?lgerne af Slesvigs deling ? 1920 Rainer Hering

Tvrdi uvez

44.40 €

Bioimpedanz-basierte Überwachung muskulärer Herzunterstützungssysteme Petra R. J. Margaritoff

Meki uvez

70.94 €

Nutzlosigkeit des Alters (?) Melanie Weyer

Meki uvez

16.14 €

Manual de La Iglesia del Nazareno, 2013-2017 2013-2017 Iglesia Del Nazareno

Meki uvez

15.53 €

Wirbelschicht-Sprühgranulation Hans Uhlemann

Meki uvez

75.18 €

Gelingende Partizipation Ludger Pesch

Meki uvez

23.61 €

Decídete, 3 Claves para salir de Deudas: Emprende nuevos proyectos y vive en paz con tus finanzas Marisol Lopez

Meki uvez

9.38 €

Historia, trajes y condecoraciones de todas las órdenes de caballería e insignias de honor tomo 2 Artigas

Tvrdi uvez

79.32 €

elefante en la oscuridad Idries Shah

Tvrdi uvez

15.73 €

Seeds of Peace, Arabic Elsa M Rubio

Meki uvez

10.28 €

Die deutsche AGB-Kontrolle und nicht im Einzelnen ausgehandelte Klauseln im europäischen Vertragsrecht. Eine rechtsvergleichende Untersuchung zur Refo Jianyi Wang

Meki uvez

28.45 €

HISTORIA MUNDO CONTEMPORANEO 1 BACHILLERATO Cortada Cortada

Meki uvez

56.51 €

Reponse A A.-R. Dillon A La Demande Du Don Gratuit Et de la Capitation Dillon

Meki uvez

12.71 €

Safety, efficacy, and legal concerns surrounded the Department of Defense (DoD) Anthrax Vaccine Immunization Program (AVIP) in the early and mid-2000s. Production capacity, patient refusals, and legal injunctions limited vaccine delivery during this time period. Since 2007, the Anthrax Vaccine Adsorbed (AVA) has been administered to all service members deploying to high-risk areas except those medically or administratively exempt. This thesis evaluates the current AVIP in terms of associated risks and benefits. Aggregate data from long-term studies and review by multiple scientific organizations, both within and external to the DoD, suggest that the AVA is both safe and efficacious. The DoD has tailored the current AVIP policy to protect forces with anticipated high exposure risk. This tailored vaccination policy minimizes vaccine-associated risk for individuals and for the force. Current AVIP benefits for individuals and for force protection outweigh the risks. As risks and benefits change over time, ongoing assessment is essential to ensure that individual and force health promotion are optimized. Continuing long-term scientific safety and efficacy research, ongoing educational efforts, and recognition of patient concerns are essential for the continued success of the AVIP and other force protection programs.